Dr. Jie Zheng's research combines chemical, computational, structural and systems biology with therapeutic development. In an effort to better understand the biological functions of different signaling pathways in the visual system and to explore the therapeutic potential of targeting abnormal signaling pathways, his laboratory focuses on structure-based drug discovery with an emphasis on developing proteins and small molecules that can systematically modulate signal transduction pathways. In addition, his laboratory is interested in structure-based drug repositioning.
Lee HJ, Bao J, Miller A, Zhang C, Wu J, Baday YC, Guibao C, Li L, Wu D, Zheng JJ. Structure-based Discovery of Novel Small Molecule Wnt Signaling Inhibitors by Targeting the Cysteine-rich Domain of Frizzled. J Biol Chem. 2015 Dec 18;290(51):30596-606. doi: 10.1074/jbc.M115.673202. Epub 2015 Oct 26.
Vanarotti MS, Miller DJ, Guibao CD, Nourse A, Zheng JJ. Structural and mechanistic insights into the interaction between Pyk2 and paxillin LD motifs. J Mol Biol. 2014 Dec 12;426(24):3985-4001. doi: 10.1016/j.jmb.2014.08.014. Epub 2014 Aug 29.
Bao J, Lee HJ, Zheng JJ. Genome-wide network analysis of Wnt signaling in three pediatric cancers. Sci Rep. 2013 Oct 17;3:2969. doi: 10.1038/srep02969.
Li X, Shan J, Chang W, Kim I, Bao J, Lee HJ, Zhang X, Samuel VT, Shulman GI, Liu D, Zheng JJ, Wu D. Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism. Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11402-7. doi: 10.1073/pnas.1205015109. Epub 2012 Jun 25.
Shan J, Zhang X, Bao J, Cassell R, Zheng JJ. Synthesis of potent dishevelled PDZ domain inhibitors guided by virtual screening and NMR studies. Chem Biol Drug Des. 2012 Apr;79(4):376-83. doi: 10.1111/j.1747-0285.2011.01295.x. Epub 2012 Jan 30.